MET and hepatocellular carcinoma: As an oral tyrosine kinase inhibitor that can inhibit the growth of multiple tumors by inhibiting various receptor tyrosine kinases (RTKs) (e.g., VEGFR2, c-MET), cabozantinib is approved for the treatment of patients with HCC that have been previously treated with sorafenib.